ArticleCancer discovery2022
Think Globally, Act Locally: Globalizing Precision Oncology.
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.Health affairs scholar · 2026Review
- Real-World Comparison of Gene-Matched vs. Non-Gene-Matched Therapy Outcomes Using Integrated Genomic and Clinical Data.Cancer science · 2025Article
- The Molecular Tumor Board Turns 10: The Age of Complexity.The oncologist · 2025Article
- Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.Surgical oncology clinics of North America · 2024Review
- Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer:Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
summaryGlobalizing precision oncology should be a major priority for cancer care in the upcoming decades. In this issue, the K-MASTER study provides a framework for infrastructure building in East Asia illustrating the widening global potential of precision oncology. It is time to modify the precision oncology mantra: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally. See related article by Park et al., p. 938 (3).
Indexed as
Identifiers
35373284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.